The prevalence and mechanisms of antibiotic resistance of Helicobacter pylori have not yet been investigated in Uruguay. The objective of this study was to assess the susceptibility of H. pylori to the most frequently used antibiotics and to determine the mechanism of resistance to clarithromycin. Seventy-nine isolates were obtained from gastric biopsies of 50 adult patients during two periods, 2001 and 2006. The former group enrolled the general population (GP), the latter group Afro-descendant (AD) subjects. The minimum inhibitory concentrations of clarithromycin, amoxicillin, tetracycline, metronidazole, and levofloxacin were determined using the E-test technique. Amplification was achieved through PCR and nucleic acid sequencing to detect mutations in the site of action of clarithromycin in the rRNA gene 23S. No amoxicillin or tetracycline-resistant strains were found. Clarithromycin resistance was found in 12% of the patients overall: 19.4% resistance in AD patients and no resistance in the GP group. This difference was statistically significant. The highest resistance was seen with metronidazole (36%), present in similar proportions in the two groups: 36.8% (GP) and 35.5% (AD). One GP patient and one AD patient had levofloxacin-resistant strains. Sequencing analysis of gene 23S rRNA showed that only mutation in position 2143 was presented in all clarithromycin-resistant strains.Key words: H. pylori. Clarithromycin resistance. Uruguay. INTRODUCTIONHelicobacter pylori infection of the gastric mucosa is associated with chronic gastritis, gastro-duodenal ulcer, gastric adenocarcinoma and MALT lymphoma (1-3).Therefore, eradication of the infection is imperative as soon as the presence of the bacteria is confirmed in the setting of one of the above conditions in order to allow ulcers to heal and reduce the risk of developing gastric cancer (4,5).Therapy is based on combinations of antimicrobials and proton pump inhibitors and is usually prescribed empirically, without any susceptibility testing. Although H. pylori may be susceptible to many antibiotics in vitro, in reality, very few agents can be used to treat the infection in vivo. Several therapy schemes have been evaluated for the eradication of H. pylori. Most consensus groups accept that so-called triple therapy (6) is the best choice available. Triple therapy consists of a proton-pump inhibitor combined with two antimicrobials, amoxicillin and clarithromycin as first line agents. However, using this regimen, therapy failures have been reported in up to 15-40% of cases (7-9). Other therapies available for patients with persistent infection include substituting the antimicrobials with metronidazole, tetracycline, or levofloxacin, or adding a bismuth-derived product (10). Tenday sequential therapy: five days of treatment with a proton-pump inhibitor and amoxicillin followed by five days of treatment with the proton-pump inhibitor and two other antibiotics (usually clarithromycin and a 5-nitroimidazole) has also been proposed. A recently published met...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.